Suvodirsen
As of the edition of 20 October 2026, Suvodirsen is an oligonucleotide: stopped in 2020; acts on DMD.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Oligonucleotide
- Registered trials
- 2, 1 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Suvodirsen.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DMD | Dystrophin | P11532 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Wave Life Sciences | Lead sponsor of trials | 2018 to now |